Clinical Trial

Clinical Study of DA-002 and DA-005 As a Treatment for Hair Loss

Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated December 19, 2024 (before its estimated October 17, 2025 completion). Its status may not reflect the trial's current state.
Summary
The primary objective of the study is to assess the safety and efficacy of DA-005 and DA-002 as a treatment for hair loss (androgenetic alopecia).
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2024-07-12; most recent amendment 2024-12-17.
Trial Details
NCT Number NCT06501924
Lead Sponsor Applied Biology, Inc.
Collaborators: Follea International Limited, Daniel Alain, Inc.
Conditions Androgenetic Alopecia, Female Pattern Baldness, Male Pattern Baldness
Enrollment 516 participants
Start Date 2025-01-15
Primary Completion 2025-10-17 (estimated)
Study Completion 2025-12-12 (estimated)
Updated on ClinicalTrials.gov 2024-12-19